CompletedPhase 3

Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet

France720 participantsStarted 2019-01-25

Plain-language summary

All the patients admitted in emergency department for minor traumatized cranial, with antiplatelet therapy, can be included, after checked inclusion and non inclusions criterias. If they are agree, a blood sample for the dosage of S100b will be done. No other modification of the medical care, all patients will have tomodensitometria, according with recommendations. The aim of the study is to validate the negative predictive value of S100b in this population.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 Years old * Minor traumatic brain injury measured by a Glasgow score between 13 and 15 * Antiplatelet agent therapy * Free subject without tutorship or curatorship Exclusion Criteria: * Age \< 18 years old * Glasgow score \<13 * Traumatic brain injury older than 6 hours * Patient without any social security system * Patient with renforced protection (tutorship, curatorship, …)

What they're measuring

Brain scanner Detection of a cerebral lesion requiring a surgery or medical intervention or an hospitalisation for a patient who have serum level of S100B protein with the treshold of 0.105 μg/L

Timeframe: 3 hours

Trial details

NCT IDNCT03780062

SponsorPoitiers University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-04-28

View on ClinicalTrials.gov More Minor Traumatic Brain Injury trials